Results 181 to 190 of about 26,268,552 (306)

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

Advances in First-Line Treatment of Classical Hodgkin Lymphoma in the Era of Novel Agents. [PDF]

J Clin Med
Barefah AS.
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. [PDF]

NPJ Precis Oncol
Cole S, Campitelli P, Grieb B, Astsaturov I, Von Hoff D, Singh H, Pishvaian MJ, Bekaii-Saab TS, Hosein PJ, Philip PA, Helmstetter A, Maney T, Ribeiro JR, Hamrick J, Magee D, Spetzler D.   +15 more
europepmc   +1 more source

Laser trabeculoplasty as first-line glaucoma treatment [PDF]

The Lancet, 2019
Jonathan W, Young, Joesph, Caprioli
openaire   +2 more sources

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Efgartigimod as a salvage therapy for anti-NMDAR encephalitis patients after first-line treatment failure: a case series. [PDF]

Front Neurol
Zhang Y, Song Z, Zheng L, Liang L, Zhao H, Bu H.   +5 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma. [PDF]

Am J Transl Res
Li Z, Xu Z, Wang L, Mao X, Huo T, Jin C.
europepmc   +1 more source

First-line Treatment for AOMT [PDF]

Ear, Nose & Throat Journal, 2005
openaire   +1 more source